Abstract
Besides well-known effects in GH-secreting adenomas, somatostatin analogs such as octreotide and lanreotide have been used in TSH-secreting adenomas and in the so-called clinically nonfunctioning adenomas. The rationale for their use is based on the evidence that both these tumor types express large amounts of somatostatin receptor subtypes 2 and 5, which are preferentially bound by octreotide and lanreotide. However, whether in TSH-secreting adenomas the results are excellent in the nonfunctioning type, the results are controversial. Some preliminary results showing a very rapid recovery of the visual field have not been confirmed subsequently. No evident effect of tumor shrinkage has been reported. At present, the use of somatostatin analogs in clinically nonfunctioning adenomas is questioned.
Similar content being viewed by others
References
Guillemin, R. (1978). Science 202, 390–402.
Guillemin, R. (1981). J. Endocrinol. 90, 3–10.
Lamberts, S. W., Krenning, E. P., and Reubi, J. C. (1991). Endocr. Rev. 12, 450–482.
Newman, C. B., Melmed, S., George, A., et al. (1998). J. Clin. Endocrinol. Metab. 83, 3034–3040.
Lamberts, S. W. J., van der Lely, A.-J., de Herder, W. W., and Hofland, L. J. (1996). N. Engl. J. Med. 334, 246–254.
Morange I, de Boisvilliers F, Chanson P, et al. (1994). J. Clin. Endocrinol. Metab. 79, 145–151.
Giusti, M., Gussoni, G., Cuttica, C. M., Giordano, G., and the Italian Multicenter Slow Release Lanreotide Study Group. (1996). J. Clin. Endocrinol. Metab. 81, 2089–2097.
Gillis, J. C., Noble, S., and Goa, K. L. (1997). Drugs 53, 681–699.
Colao, A., Ferone, D., Marzullo, P., et al. (2001). J. Clin. Endocrinol. Metab. 86, 2779–2786.
Beck-Peccoz, P., Brucker-Davis, F., Persani, L., Smallridge, R. C., and Weintraub, B. D. (1996). Endocr. Rev. 17, 610–638.
Brucker-Davis Oldfield, E. H., Skarulis, M. C., Doppman, J. L., and Weintraub, B. D. (1999). J. Clin. Endocrinol. Metab. 84, 476–486.
Freda, P. U. and Wardlaw, S. L. (1999). J. Clin. Endocrinol. Metab. 84, 3859–3866.
Bevan, J. S., Webster, J., Burke, C. W., and Scanlon, M. F. (1992). Endocr. Rev. 13, 221–235.
Bertherat, J., Brue, T., Enjalbert, A., et al. (1992). J. Clin. Endocrinol. Metab. 75, 540–546.
Losa, M., Magnani, P., Mortini, P., et al. (1997). Eur. J. Nucl. Med. 24, 728–731.
Comi, R. J., Gesunheit, N., Murray, L., Gorden, P., and Weintraub, B. D. (1987). N. Engl. J. Med. 317, 12–17.
Chanson, P., Weintraub, B. D., and Harris, A. G. (1993). Ann. Intern. Med. 119, 236–240.
Fukuda, T., Yokoyama, N., Tamai, M., et al. (1998). Intern. Med. 37, 1027–1030.
Gancel, A., Vuillermet, P., Legrand, A., Catus, F., Thomas, F., and Kuhn, J. M. (1994). Clin. Endocrinol. 40, 421–428.
Kuhn, J. M., Arlot, S., Lefebvre, H., et al. (2000). J. Clin. Endocrinol. Metab. 85, 1487–1491.
Caron, P., Arlot, S., Bauters, C., et al. (2001). J. Clin. Endocrinol. Metab. 86, 2849–2853.
Katnelson, L., Alexander, J. M., and Klibanski, A. (1993). J. Clin. Endocrinol. Metab. 76, 1089–1094.
Ebersold, M. J., Quast, L. M., Laws, E. R., Scheitauer, B., and Randall, R. V. (1986). J. Neurosurg. 64, 713–719.
Harris, P. E., Afshar, F., Coates, P., et al. (1989). Q. J. Med. 71, 417–427.
Colao, A., Cerbone, G., Cappabianca, P., et al. (1998). J. Endocrinol. Invest. 21, 284–290.
Littley, M. D., Shalet, S. M., Beardwell, C. G., Ahmed, S. R., Applegate, G., and Sutton, M. I. (1989). Q. J. Med. N. Series 70, 145.
Turner, H. E., Stratton, I. M., Byrne, J. V., Adams, C. B., and Wass, J. A. (1999). Clin. Endocrinol. 51, 281–284.
Lamberts, S. W. J., de Herder, W. W., van der Lely, A. J., and Hofland, L. J. (1995). Endocrinologist 5, 448–451.
Ferone, D., Lastoria, S., Colao, A., et al. (1998). J. Clin. Endocrinol. Metab. 83, 248–252.
Colao, A., Ferone, D., Lastoria, S., et al. (2000). Clin. Endocrinol. 52, 437–445.
Faglia, G., Bazzoni, N., Spada, A., et al. (1991). J. Clin. Endocrinol. Metab. 73, 850–856.
Plockinger, U., Reichel, M., Fett, U., Saeger, W., and Quabbe, H. J. (1994). J. Clin. Endocrinol. Metab. 79, 1416–1423.
Duet, M., Mundler, O., Ajzenberg, C., et al. (1994). Eur. J. Nucl. Med. 21, 647–650.
Florio, T., Thellung, S., Arena, S., et al. (1999). Eur. J. Endocrinol. 141, 396–408.
Colao, A., Lastoria, S., Ferone, D., et al. (1999). J. Endocrinol. Invest. 22, 176–183.
Warnet, A., Harris, A. G., Renard, E., Martin, D., James-Deidier, A., Chaumet-Riffaud, P., and the French multicenter octreotide study group. (1997). Neurosurgery 41, 786–797.
De Bruin, T. W. A., Kwekkeboom, D. J., van’t Verlaat, J. W., et al. (1992). J. Clin. Endocrinol. Metab. 75, 1310–1317.
van Hagen, P. M., Baarsma, G. S., Mooy, C. M., et al. (2000). Eur. J. Endocrinol. 143(Suppl. 1), S43-S51.
Wagenaar, A. H., Harris, A. G., van der Lely, A. J., and Lamberts, S. W. (1991). Acta Endocrinol. (Copenh.) 125, 637–642.
Flogstad, A. K., Halse, J., Grass, P., et al. (1994). J. Clin. Endocrinol. Metab. 79, 461–465.
Lombardi, G., Colao, A., Ferone, D., et al. (1995). Eur. J. Endocrinol. 132, 559–564.
Marzullo, P., Ferone, D., Di Somma, C., et al. (1999). Pituitary 1, 115–120.
Rocheville, M., Lange, D. C., Kumar, U., Patel, S. C., Patel, R. C., and Patel, Y. C. (2000). Science 288, 154–157.
Andersen, M., Bjerret, P., Schroder, H. D., et al. (2001). Clin. Endocrinol. 54, 23–30.
Jaquet, P., Ouafik, L., Saveanu, A., et al. (1999). J. Clin. Endocrinol. Metab. 84, 3268–3276.
Shimon, I., Yan, X., Taylor, J. E., Weiss, M. H., Culler, M. D., and Melmed, S. (1997). J. Clin. Invest. 100, 2386–2392.
Culler, M. D., Taylor, J. E., and Moreau, J. P. (2002). Ann. Endocrinol. (Paris) 63, 2S5–12.
Weckbecker, G., Briner, U., Lewis, I., and Bruns, C. (2002). Endocrinology 143, 4123–4130.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Colao, A., Filippella, M., Di Somma, C. et al. Somatostatin analogs in treatment of non-growth hormone-secreting pituitary adenomas. Endocr 20, 279–283 (2003). https://doi.org/10.1385/ENDO:20:3:279
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1385/ENDO:20:3:279